Experts outline treatment options for patients with venetoclax resistance.
Researchers sought to determine whether combination therapy with temsirolimus and lenalidomide would have therapeutic activity in patients with heavily pretreated lymphomas.
Response and survival outcomes were similar with rituximab biosimilars and the originator.
Researchers sought to determine whether patients with relapsed or refractory classical Hodgkin lymphoma can receive benefit when retreated with nivolumab.
Researchers sought to determine whether patients with lymphoma would develop antibodies with a COVID-19 vaccine 6 months after treatment with anti-CD20-containing therapy.
Researchers sought to determine whether there is a role for extracellular vesicles associated with follicular lymphoma B cells in the alteration of bone marrow stroma.
Researchers sought to determine the fertility-related issues and approaches for survivors of Hodgkin lymphoma and diffuse large B-cell lymphoma.
Researchers sought to determine whether baseline SUVmax would have prognostic value in patients with follicular lymphoma.
A retrospective study revealed age-based risks for toxicities in patients with NHL treated with high-dose chemotherapy and autologous hematopoietic cell transplantation.
This case study showed that B-cell type primary central nervous system lymphoma may rapidly progress following dimethyl fumarate treatment in patients with relapsing remitting MS.
Circulating tumor DNA may identify patients at risk of relapse after axicabtagene ciloleucel.
Researchers sought to determine how chemoimmunotherapies can affect FDG-PET parameters and influence interpretation of results in patients with FL.
Researchers sought to determine whether patients with PCNSL who are not eligible for clinical trials may benefit from high-dose methotrexate.
Researchers sought to determine whether adding brentuximab vedotin to chemotherapy would be safe and effective in pediatric patients with ALCL.
Researchers sought to develop a low-cost, machine learning-based approach to diagnosing paraffin-embedded lymphoma biopsy specimens.
In a review, researchers explained diagnostic features associated with the rare condition of nodular lymphocyte-predominant Hodgkin lymphoma.
Researchers compared outcomes in patients with PCNSL who did not meet clinical trial criteria with those of patients from a major multicenter clinical trial of PCNSL.
Researchers sought to determine whether the presence of LRPAP1 autoantibodies may predict clinical outcomes in patients with MCL.
Researchers sought to identify a new possible immune-related mechanism of action associated with chidamide for treatment of patients with PTCL.
Researchers sought to determine whether zanubrutinib would have a high response rate and extended progression-free survival in patients with R/R mantle cell lymphoma.
Researchers sought to determine whether a novel model that combines signatures of metabolic dysregulation with clinical features may aid in clinical decision-making among patients with DLBCL.
Researchers sought to determine whether fixed-duration chemotherapy-free treatment with obinutuzumab and idelalisib would be effective in patients with R/R WM.
Researchers sought to determine the maximum and recommended phase 2 dose for loncastuximab tesirine in patients with B-cell NHL.
Researchers are seeking to compare the efficacy and safety of the combination of ibrutinib and venetoclax compared with ibrutinib and placebo in patients with mantle cell lymphoma.
Researchers sought to determine which hematopoietic stem cell transplantation procedure is more efficacious for patients with refractory/relapsed peripheral T-cell lymphoma.
A review of the literature identified common deficits in cognitive functioning experienced by survivors of pediatric cancers.
Researchers sought to identify possible prognostic markers in extranodal natural killer T-cell lymphoma through an analysis of gene expression profiling data.
Researchers sought to determine whether first-line chemotherapy followed by high-dose therapy and auto-SCT would be the preferred treatment for patients under 60 with T-NHL.
In patients who had received at least 2 prior therapy lines, the overall response rates were 49.9% in SCHOLAR-5 vs 94.2% in ZUMA-5.
The overall response rate was 44.7% after a median follow-up of 15 months.
The median overall survival was not reached at 3 years.
The 7-year survival results were superior with MATRIX.
Relapsed/refractory disease and older age were also associated with prolonged hospital stay and death.
Researchers sought to identify factors that may contribute to failure with CAR T cell therapy in patients with LBCL.
Six patients experienced a grade 5 treatment-related adverse event.
This analysis compared infection-related hospitalization and death among patients 70 years of age and older with DLBCL treated with full-dose vs attenuated-dose R-CHOP.
Zanubrutinib is marketed under the trade name Brukinsa and is currently indicated for the treatment of mantle cell lymphoma.
Researchers sought to determine whether pirtobrutinib would be effective and tolerable in heavily pretreated patients with mantle cell lymphoma.
Researchers sought to determine whether combining nivolumab with brentuximab vedotin would be safe and effective in treating patients with mediastinal gray zone lymphoma.
Zynlonta (loncastuximab tesirine-lpyl) is a CD19-directed antibody and alkylating agent conjugate.
Researchers sought to investigate the associations between PTSS and the experiences of pediatric survivors of Hodgkin lymphoma treated in the AHOD0031 study.
Baseline alcohol consumption was associated with a higher QOL score compared with never use of alcohol.
Researchers sought to update and assess the interim efficacy, futility, and safety in the phase 3 SPARKLE trial.
Investigators report on findings from the MARIETTA study, which evaluated an intensive, CNS-directed chemoimmunotherapy followed by autoHSCT in patients with secondary CNS lymphoma.
Combination therapy of anti-PD-1 camrelizumab plus decitabine led to longer response in patients with relapsed/refractory Hodgkin lymphoma.
Researchers sought to determine the safety and efficacy of brentuximab vedotin in pediatric patients with classical Hodgkin lymphoma.
Researchers sought to determine whether AB-205 would be a safe and effective therapy added to HDT-AHCT in adult patients with lymphoma.
An international, retrospective study was conducted to assess outcomes following alloHCT after PD-1 blockade in Hodgkin lymphoma.
Researchers sought to determine whether hypomagnesemia increases the risk of failure for autologous hematopoietic stem cell transplantation in patients with DLBCL.
A team of investigators sought to determine if treatment efficacy can be maintained without radiotherapy among patients with newly diagnosed, early-stage, unfavorable Hodgkin lymphoma.
Researchers sought to determine whether R-MegaCHOEP would improve outcomes compared to R-CHOEP-14 in patients with newly diagnosed, aggressive B-cell lymphoma.